Aroa Biosurgery (ARX) Q4 2025 earnings summary

Executive summary

• Achieved two consecutive quarters of positive operating cash flow, with NZ$1.1 million generated in Q1 2025 and a robust cash balance of NZ$22 million at quarter-end, remaining debt-free.

• Reaffirmed full-year revenue guidance of NZ$81–84 million (17–22% growth year-over-year) and normalized EBITDA of NZ$2–4 million, with constant currency guidance slightly lower.

• Myriad product sales grew 11% sequentially and 32% year-over-year, reaching a record US$2 million in March 2025.

• TelaBio reported full-year revenue of US$69.3 million, up 19% year-over-year, with Ovitex sales to TelaBio up 17%.

• Over 100 peer-reviewed studies now published validating the efficacy and safety of the ECM platform, with three new case studies this quarter.

Financial highlights

• Cash receipts for the quarter totaled NZ$20.1 million.

• Positive operating cash flow of NZ$1.1 million for the quarter, with NZ$0.6 million in CapEx outflows.

• Ended the quarter with a cash balance of NZ$22 million and remained debt-free.

• Aggregate NZ$185,000 paid to non-executive directors as fees during the quarter.

• Unused financing facilities available: NZ$719,000.

Outlook and guidance

• Full-year revenue guidance maintained at NZ$81–84 million, normalized EBITDA at NZ$2–4 million; constant currency guidance: revenue NZ$76–79 million, EBITDA up to NZ$2 million.

• Expect continued strong growth from TelaBio and Myriad, though growth rates may moderate as baseline increases.

• Anticipate further improvement in cash flow and profitability in the coming year.

• Full year financial results to be reported on 27 May 2025.